Headlands Technologies LLC Has $4.91 Million Stock Position in Icon Plc $ICLR

Headlands Technologies LLC increased its stake in Icon Plc (NASDAQ:ICLR) by 242.7% during the second quarter, HoldingsChannel reports. The firm owned 33,780 shares of the medical research company’s stock after acquiring an additional 23,924 shares during the period. Headlands Technologies LLC’s holdings in Icon were worth $4,913,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Artisan Partners Limited Partnership lifted its position in shares of Icon by 67.4% in the second quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock worth $1,045,039,000 after purchasing an additional 2,893,946 shares in the last quarter. Financiere des Professionnels Fonds d investissement inc. increased its stake in Icon by 31.0% in the 2nd quarter. Financiere des Professionnels Fonds d investissement inc. now owns 50,212 shares of the medical research company’s stock valued at $7,303,000 after buying an additional 11,894 shares during the period. American Century Companies Inc. lifted its position in Icon by 11.2% in the 2nd quarter. American Century Companies Inc. now owns 531,395 shares of the medical research company’s stock worth $77,292,000 after buying an additional 53,458 shares in the last quarter. Equity Investment Corp purchased a new stake in Icon in the 2nd quarter worth approximately $82,264,000. Finally, DAVENPORT & Co LLC acquired a new stake in shares of Icon during the 2nd quarter valued at $403,000. 95.61% of the stock is owned by hedge funds and other institutional investors.

Icon Stock Performance

ICLR opened at $186.58 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The company has a market cap of $15.07 billion, a PE ratio of 25.25, a price-to-earnings-growth ratio of 3.41 and a beta of 1.25. The stock has a 50-day moving average of $176.51 and a 200-day moving average of $166.68. Icon Plc has a 52-week low of $125.10 and a 52-week high of $228.29.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Icon in a report on Monday, December 1st. UBS Group set a $220.00 target price on Icon in a research report on Friday, October 24th. TD Cowen reduced their price target on Icon from $183.00 to $172.00 and set a “hold” rating for the company in a report on Friday, October 24th. Leerink Partners set a $220.00 price target on Icon in a research note on Thursday, October 23rd. Finally, Cowen reaffirmed a “hold” rating on shares of Icon in a research report on Friday, October 24th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $205.00.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.